Abstracts
were matched on number of medications and number of chronic diseases. The health behavior was PPMTM participation. Outcomes were changes in: 1) Number of MHRPs; 2) Medication adherence using medication possession ratio (MPR); and 3) Total drug costs. Multivariate regression was used for group comparisons of outcomes. RESULTS: The intervention (n 60) and control (n 60) groups were not statistically different in predisposing or need factors except for gender (intervention 51.7% male; control 28.3% male; p 0.009). At baseline, 4.8 ( 2.7) MHRPs were identifi ed in the intervention group and 9.2 ( 2.9) in the control group. At the 6-month follow-up, 2.5 ( 2.0) and 7.9 ( 3.0) MHRPs remained, respectively. Multivariate regression revealed that the intervention group had signifi cantly more MHRPs resolved (p 0.0003) when compared to the control group, while controlling for predisposing and need factors. There were no other signifi cant predictors of MHRP resolution, Analyses showed no signifi cant predictors of change in MPR or total drug costs from baseline to 6-month follow-up. CONCLUSIONS: A telephone MTM program was effective in resolving MHRPs among Medicare benefi ciaries; however, no signifi cant differences existed between the intervention and control groups in medication adherence and total drug costs. A total of 1,888,682 patients met our inclusion criteria. Mean age ( SD) was 71.6 ( 11.6) years, 59.5% were female, and 66.4% were white. Approximately 58.9%, 5.8%, 0.5% had coexisting hypertension, nephropathy, and hypertension nephropathy. Overall, 56.9% were receiving ACEI/ARB therapy. Logistic regression indicated that patients with coexisting hypertension nephropathy and hypertension were 72% and 36% more likely to use ACEI/ARB compared to patients without hypertension and/or nephropathy. However, patients with nephropathy were 24% less likely to receive ACEI/ARB therapy. Females, older patients, and patients of nonwhite races were also more likely to use ACEI/ARB. Patients with myocardial infarction, sleep apnea, coronary artery disease, retinopathy or heart failure were more likely to have used ACEI/ARB, while the opposite was true for those with hypercholesterolemia, peripheral vascular, cerebrovascular, or chronic obstructive pulmonary diseases. All results were statistically signifi cant at P .0001 level. CONCLUSIONS: Less than 60% of Medicare Part D enrollees with diabetes received ACEI/ARB therapy. Several patient characteristics can predict ACEI/ARB use. Opportunities exist for qualityimprovement interventions that could increase the outcomes for high-risk patients.
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MD6 PREDICTORS OF UTILIZATION OF ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS AMONG MEDICARE PART D ENROLLEES WITH DIABETES
MD7 DOES MEDICARE HAVE AN IMPLICIT COST-EFFECTIVENESS THRESHOLD?
Chambers J J 1 , Neumann PJ 2 , Buxton MJ 3 1 Mapi Values, Boston, MA, USA, 2 Tufts Medical Center, Boston, MA, USA, 3 Brunel University, Uxbridge, Middlesex, UK OBJECTIVES: Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) maintains that cost-effectiveness is not considered in national coverage determinations (NCDs) for medical technologies. Our objective was to assess the cost-effectiveness of technologies and interventions that are the subject of Medicare NCDs in order to investigate whether an implicit cost-effectiveness threshold exists. In addition, we explored whether CMS have cited cost-effectiveness evidence in NCDs. METHODS: We reviewed NCD decision memos from 1999 through 2007 (n 103). A literature review was conducted for each coverage decision to fi nd relevant economic evaluations. The economic evaluation that best represented each coverage decision was included in a review of the cost-effectiveness of medical technologies considered in NCDs. RESULTS: Sixty-four coverage decisions were identifi ed from 103 decision memos. Fifty were associated with a positive coverage decision and 14 with a non-coverage decision. Of the positive decisions, 22 were associated with an economic evaluation that estimated the medical intervention to be dominant (costs less and more effective than the alternative), 8 with an incremental cost-effectiveness ratio (ICER) of less than $50,000, 8 with an ICER greater than $50,000 but less than $100,000, and 8 with an ICER greater than $100,000 (2008 USD). In four of the positive coverage decisions the intervention was dominated (costs more and was less effective than the alternative). Of the non-coverage decisions, 3 interventions were estimated to be dominant, 6 were associated with an ICER less than $30,000, one with an ICER of approximately $200,000, and four were dominated. Fourteen decision memos cited or discussed cost-effectiveness information. CONCLUSIONS: CMS is covering a number of interventions that do not appear to be cost-effective by traditional standards. While we identifi ed several instances where cost-effectiveness evidence was cited in NCDs, we found no clear evidence of an implicit constant fi xed cost-effectiveness threshold. The proportion of out of pocket expenditures in total pharmacy reimbursement dropped 7.62% (from 40.43% to 32.81%) for antidepressants, 6.24% for antipsychotics (from 27.82% to 21.58%), but increased 12.15% for benzodiazepines (from 62.64% to 74.79%), and 9% (from 71.96% to 80.56%) for barbiturates. Dual eligible benefi ciaries were the group most severely affected by the policy change. For dual eligible benefi ciaries who were on any of the four drug categories, their yearly out of pocket expense increased extensively. The most dramatic change was observed in dual eligibles using benzodiazepines. Their out of pocket expenditure increased by around 12 folds from 2005 to 2006. Non-dual Part D enrollees benefi ted the most from the new drug policy. The most signifi cant cost saving was found in non-dual Part D enrollees who were on antidepressants (from 62.23% to 32.97%) and antipsychotics (from 55.24% to 38.30%). CONCLUSIONS: The implementation of Part D was associated with reduced out of pocket psychotropic prescription burden on non-dual Part D enrollees, however, out-of -pocket burden on the dual eligible benefi ciaries severely increased.
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